From wiki-pain
Revision as of 19:29, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1977
Last Reported 1999
Negated 0
Speculated 1
Reported most in Abstract
Documents 9
Total Number 10
Disease Relevance 0.81
Pain Relevance 3.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

carbohydrate metabolic process (GUSB) lysosome (GUSB)
Anatomy Link Frequency
neutrophils 5
peritoneal macrophages 1
GUSB (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 8 99.96 Very High Very High Very High
cINOD 19 98.72 Very High Very High Very High
agonist 3 98.24 Very High Very High Very High
Enkephalin 7 95.08 Very High Very High Very High
diclofenac 12 92.44 High High
lidocaine 9 91.32 High High
local anesthetic 5 90.88 High High
Inflammation 8 90.24 High High
opiate 2 75.00 Quite High
Central nervous system 1 74.96 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 15 98.60 Very High Very High Very High
Injury 1 78.96 Quite High
Disease 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Human sera and anti-inflammatory drugs were compared for their ability to inhibit the zymosan-induced release of beta-glucuronidase from cultured rat peritoneal macrophages.
Localization (release) of beta-glucuronidase in peritoneal macrophages associated with inflammation and cinod
1) Confidence 0.80 Published 1977 Journal Br J Exp Pathol Section Abstract Doc Link 562176 Disease Relevance 0.17 Pain Relevance 0.14
Initially, it was found that 4-OH-XY was highly unstable after it was released from conjugates by beta-glucuronidase and the enzyme mixture.
Localization (released) of beta-glucuronidase
2) Confidence 0.79 Published 1990 Journal Pharm. Res. Section Abstract Doc Link 2367319 Disease Relevance 0 Pain Relevance 0.16
Tenoxicam also slightly, but not significantly, inhibited beta-glucuronidase release by isolated neutrophils induced by all the agonists used.
Localization (release) of beta-glucuronidase in neutrophils associated with agonist
3) Confidence 0.78 Published 1991 Journal Pharmacol. Res. Section Abstract Doc Link 1652137 Disease Relevance 0 Pain Relevance 0.40
In this study, the effects of tenoxicam, an oxicam derivative with a thienothiazine structure, on neutrophil activation were evaluated by the assessment of the following parameters: (1) superoxide anion generation by neutrophils and whole blood stimulated with N-formyl-methionyl-leucyl-phenylalanine (fMLP), the calcium ionophore A23187 and serum treated zymosan (STZ); (2) beta-glucuronidase release from neutrophils stimulated with fMLP, A23187 and STZ; (3) binding of [3H]fMLP to intact neutrophils.
Localization (release) of beta-glucuronidase in neutrophil
4) Confidence 0.78 Published 1991 Journal Pharmacol. Res. Section Abstract Doc Link 1652137 Disease Relevance 0.15 Pain Relevance 0.41
Our data clearly demonstrate that paracetamol glucuronide is cleaved by human beta-glucuronidase thereby releasing paracetamol.
Localization (releasing) of beta-glucuronidase associated with paracetamol
5) Confidence 0.71 Published 1999 Journal J. Chromatogr. B Biomed. Sci. Appl. Section Abstract Doc Link 10052702 Disease Relevance 0 Pain Relevance 0.68
Effects of tenoxicam on superoxide anion formation, beta-glucuronidase release and fMLP binding in human neutrophils: comparison with other NSAIDs.
Localization (release) of beta-glucuronidase in neutrophils associated with cinod
6) Confidence 0.69 Published 1991 Journal Pharmacol. Res. Section Title Doc Link 1652137 Disease Relevance 0.18 Pain Relevance 0.44
PMN were stimulated by fMet-Leu-Phe (FMLP) or phorbol myristate acetate (PMA) to elicit chemotaxis, extracellular release of beta-glucuronidase (BGL) and superoxide anion (SOA) production.
Localization (release) of beta-glucuronidase in PMN
7) Confidence 0.47 Published 1991 Journal Immunopharmacol Immunotoxicol Section Abstract Doc Link 1663527 Disease Relevance 0 Pain Relevance 0.52
MetEKamide was able to induce degranulation when present at 10(-3) and 10(-4) mmol/L as determined by release of beta-glucuronidase and lysozyme.
Spec (determined) Localization (release) of beta-glucuronidase
8) Confidence 0.36 Published 1987 Journal J Burn Care Rehabil Section Abstract Doc Link 3436973 Disease Relevance 0.08 Pain Relevance 0.67
We have studied the role of arachidonic acid (AA) metabolism in the release of lysosomal enzymes (beta-glucuronidase and lysozyme) from human polymorphonuclear leukocytes (PMNs). 5,8,11,14-Eicosatetraenoic acid (ETYA), which inhibits both the cyclo-oxygenase and the lipoxygenase pathways of AA metabolism, was found to cause a dose-dependent inhibition of lysosomal enzyme release from human PMNs induced by immunological (i.e., serum-treated zymosan: Zx) and nonimmunological stimuli (i.e., formyl methionine-containing peptide and the Ca2+ ionophore A23187).
Localization (release) of beta-glucuronidase in PMNs
9) Confidence 0.34 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.06 Pain Relevance 0.09
Cytochrome c reduction and the release of lysozyme, beta-glucuronidase, myeloperoxidase and gelatinase were measured.
Localization (release) of beta-glucuronidase
10) Confidence 0.32 Published 1987 Journal Biochem. Pharmacol. Section Abstract Doc Link 3038127 Disease Relevance 0.17 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools